Quick Answer
ADC Therapeutics SA reported Total Revenue of $81.36 million for the year ending 2025.
- ADC Therapeutics SA showed an increase of +14.9% in Total Revenue from 2024 to 2025.
- This data is from ADC Therapeutics SA's annual report (Form 10-K), filed with the SEC on March 10, 2026.
- XBRL data for this metric is available from 2022 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2023: $18.99 million | Q1 2023: $18.95 million | Q2 2023: $19.20 million | Q2 2023: $19.28 million | Q3 2023: $14.27 million | Q3 2023: $14.49 million | Q1 2024: $17.85 million | Q1 2024: $18.05 million | Q2 2024: $17.03 million | Q2 2024: $17.41 million | Q3 2024: $18.02 million | Q3 2024: $18.46 million | Q1 2025: $23.03 million | Q1 2025: $17.40 million | Q2 2025: $18.09 million | Q2 2025: $18.84 million | Q3 2025: $15.75 million | Q3 2025: $16.43 million.
- Over the full 6 years of available data (2022 to 2025), ADC Therapeutics SA's Total Revenue has declined by 61.2%.
- Historical annual values: Fiscal year 2025: $81.36 million | Fiscal year 2024: $70.84 million | Fiscal year 2023: $69.56 million | Fiscal year 2023: $69.06 million | Fiscal year 2022: $74.91 million | Fiscal year 2022: $209.91 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: